John Fanikos Praises Nathan Connell’s Efforts on Hemophilia Gene Therapy in Boston
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared a post on LinkedIn:
“Hemophilia historically has been seen as a ‘royal disease’ because of its occurrence in the royal families of Spain, Germany and Russia.
Today it is known as a genetic disorder where bleeding occurs because of low levels of blood clotting Factor 8 (VIII) or Factor 9 (IX). As simple as a missing gene on a chromosome that provides the blueprint for the protein Factor.
Enter gene therapy.
Kudos to Dr Nathan Connell, who worked feverishly to bring this treatment to the Boston area.
You can hear the treatment results of his first patient on the CBS news and follow his expertise at the Vasculearn Network”
Nathan Connell’s first patient results featured on CBS News.
Follow his expertise on the Vasculearn Network.
Stay informed with Hemostasis Today.
-
Aug 25, 2026, 11:48GPAS 2026 Advancing Access and Equity in Bleeding Disorders – WFH
-
Aug 25, 2026, 11:41Gregory Lip: Don’t Miss – €1,000 Mechanical Thrombectomy Grant
-
Aug 25, 2026, 11:35Applications Now Open for ASH26 Scientific Workshops
-
Aug 25, 2026, 11:34Louise St. Germain Bannon: ISTH is Looking for a Director of Strategic Partnerships and Business Development
-
Aug 25, 2026, 11:25Wolfgang Miesbach: Haemophilia and Ageing – A Joint ISTH/EAHAD Session at ISTH 2026
-
Aug 25, 2026, 11:18Caitlin Raymond: Your Blood Type Doesn’t Define Your Personality
-
Aug 25, 2026, 11:18N. Mariana S. Vasquez: USMLE Key Differences – Marfan Syndrome vs. Homocystinuria
-
Aug 25, 2026, 11:16Miguel Bronchud: Making Monoclonal Antibodies Safer in Pregnancy
-
Aug 25, 2026, 11:14Natalie Arnold: Germany Recognizes Low-Dose Colchicine in CVD Prevention